文献速递中医内科中药与中成药合理使用

康艾注射液联合铂类化疗对晚期非小细胞肺癌免疫功能影响的Meta分析

Effect of kangai injection combined with platinum-based chemotherapy on the immune function of patients with advanced non-small-cell lung cancer: A meta-analysis.
PubMed 文献 · Phytomedicine · 2022-03-31

该Meta分析纳入19项RCT、共1389例Ⅲ-Ⅳ期非小细胞肺癌患者,系统评价康艾注射液联合铂类化疗对比单纯化疗的疗效与安全性。结果显示联合治疗可显著提高客观缓解率、疾病控制率及KPS评分,改善免疫功能指标,并降低白细胞、血小板毒性及呕吐发生率。

要点

  • 康艾注射液联合铂类化疗可提高晚期NSCLC的ORR和DCR。
  • 联合治疗可改善KPS评分并降低化疗相关血液毒性及呕吐。
  • 联合治疗可提升CD3+、CD4+、NK细胞及CD4+/CD8+比值,降低CD8+。

核心结论

  • 康艾注射液联合铂类化疗较单纯化疗对晚期NSCLC患者更有利,可提高临床疗效、增强免疫功能并减轻化疗毒性。

研究设计与样本

  • 系统检索8个电子数据库至2021年7月,纳入19项关于Ⅲ-Ⅳ期NSCLC的随机对照试验,总样本量1389例。
  • 使用RevMan 5.4、Stata 16.0、TSA 0.9.5.10 Beta和GRADE Pro-GDT进行质量评价与Meta分析。

主要发现

  • 联合治疗组客观缓解率显著高于单纯化疗组[RR=1.36,95%CI(1.21,1.54),p<0.00001]。
  • 联合治疗组疾病控制率显著高于单纯化疗组[RR=1.15,95%CI(1.09,1.21),p<0.00001]。
  • 联合治疗组KPS评分改善显著优于单纯化疗组[RR=1.75,95%CI(1.41,2.18),p<0.00001]。
  • 联合治疗组白细胞毒性[RR=0.67,95%CI(0.55,0.82),p=0.0001]和血小板毒性[RR=0.60,95%CI(0.47,0.75),P<0.0001]均显著低于单纯化疗组。
  • 联合治疗组呕吐发生率显著低于单纯化疗组[RR=0.66,95%CI(0.57,0.76),p<0.00001]。

关键数值与推荐

  • 免疫功能方面,联合治疗组CD3+细胞比值显著升高[MD=10.65,95%CI(8.21,13.09),p<0.00001]。
  • 联合治疗组CD4+细胞显著升高[MD=7.67,95%CI(6.31,9.03),p<0.00001],NK细胞显著升高[MD=4.97,95%CI(3.03,6.92),p<0.00001]。
  • 联合治疗组CD4+/CD8+比值显著升高[MD=0.32,95%CI(0.19,0.45),p<0.00001],CD8+细胞百分比显著降低[MD=-5.56,95%CI(-7.51,-3.61),p<0.00001]。

临床怎么用

  • 对于Ⅲ-Ⅳ期NSCLC患者,在铂类化疗基础上联合康艾注射液可能有助于提高疗效、改善免疫功能并减轻化疗毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kangai injection (KAI) is a well-known Chinese patent medicine applied for several different types of cancers in the clinic as an auxiliary therapeutic approach, which is refined from three herbal extracts (Astragalus, Ginseng and Matrine). PURPOSE: To systematically evaluate the effect of combination treatment of platinum-based chemotherapy and KAI on patients with advanced non-small-cell lung cancer (NSCLC). STUDY DESIGN: A meta-analysis of randomized clinical trials. MATERIALS AND METHODS: The randomized controlled trials (RCTs) about stage Ⅲ-Ⅳ NSCLC using KAI combined platinum-based chemotherapy were electronically retrieved from eight electronic databases up to July 2021. We applied RevMan 5.4, Stata 16.0, TSA 0.9.5.10 Beta and GRADE Pro-GDT to evaluate the quality of the included RCTs and perform the meta-analysis. RESULTS: 19 RCTs were included, consisting a total sample size of 1,389 cases. Meta-analysis revealed that compared with chemotherapy alone, KAI combined with platinum-based chemotherapy was associated with significantly higher objective response rate (ORR) [RR = 1.36, 95%CI (1.21,1.54), p< 0.00001], higher disease control rate (DCR) [RR = 1.15, 95%CI (1.09,1.21), p< 0.00001], greater Karnofsky performance status (KPS) [RR = 1.75, 95%CI (1.41,2.18), p< 0.00001], lower white blood cell toxicity [RR = 0.67, 95%CI (0.55,0.82), p = 0.0001], lower platelet toxicity [RR = 0.60, 95%CI (0.47,0.75), P < 0.0001], and lower incidence of vomiting [RR = 0.66, 95%CI (0.57,0.76), p< 0.00001]. In terms of the immune function, KAI united with chemotherapy significantly raised the ratio of CD3+ cells [MD = 10.65, 95%CI (8.21,13.09), p< 0.00001], CD4+ cells [MD = 7.67, 95%CI (6.31,9.03), p< 0.00001], NK cells [MD = 4.97, 95%CI (3.03,6.92), p< 0.00001], and CD4+/ CD8+ [MD = 0.32, 95%CI (0.19,0.45), p< 0.00001], and decreased the percentage of CD8+ cells [MD = -5.56, 95%CI (-7.51,-3.61), p< 0.00001]. CONCLUSIONS: This meta-analysis identified that the combination treatment of KAI and platinum-based chemotherapy was more beneficial to patients with advanced NSCLC when compared to chemotherapy alone, which could significantly improve the clinical efficacy, enhance the immune function, and reduce chemotherapy toxicity. Our study provides a theoretical basis and treatment guidance for patients with NSCLC.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Zhu D, Xu Y, Feng F, et al. Effect of kangai injection combined with platinum-based chemotherapy on the immune function of patients with advanced non-small-cell lung cancer: A meta-analysis. Phytomedicine. 2022. PMID: 35397286. doi:10.1016/j.phymed.2022.154088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。